NCT03535727 2024-12-31
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
Clinical Trials
10 trialsNCT04299880 2023-11-08
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT01442649 2022-01-11
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
UNICANCER
Phase 2 Completed
NCT01660711 2021-11-08
A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Endeavor Health
Phase 2 Completed
NCT01442935 2021-06-18
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
UNICANCER
Phase 2 Completed
NCT01383538 2017-08-08
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
University of California, San Francisco
Phase 1 Completed
NCT00507091 2016-08-25
Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination
Sanofi
Phase 1 Completed
NCT00183859 2014-05-22
Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan
University of Southern California
Phase 1 Completed
NCT00813072 2012-03-02
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
PharmaEngine
Phase 2 Completed